USO 24106
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)
Disease Types: Multiple Myeloma
Eligibility Requirements:
• Documented diagnosis of MM and measurable disease
• Subject has received 1 to 2 prior lines of therapy and achieved
partial response or better to at least 1
• ECOG score of ≤ 2
• Subjects with prior CD38-directed & bortezomib therapy if
below are fulfilled:
a) Best response achieved was at least MR(bortezomib)
or PR(CD38)
b) Did not progress while receiving therapy
c) Did not discontinue due to a related AE(CD38)
d) Last dose of daratumumab was ≥ 3 months prior to
randomization(CD38)
• Subjects that received prior therapy with Iberdomide are
excluded
Available at:
- Chesapeake
- Newport News (Port Warwick III)
- Norfolk (Brock Cancer Center)
- Virginia Beach (Princess Anne)
- Williamsburg